STRO Revenue Falls 21% Yet Cash Runway Stretched to 2028

Sutro Biopharma (STRO) reported fiscal 2025 Q4 earnings on March 23, 2026, with revenue falling 21.4% year-over-year to $11.65 million. While the company missed adjusted EPS estimates, it exceeded revenue forecasts and provided optimistic guidance for 2026, including extended cash runway projections to Q2 2028.

Revenue

The total revenue of Sutro Biopharma decreased by 21.4% to $11.65 million in 2025 Q4, down from $14.81 million in 2024 Q4.

Earnings/Net Income

Sutro Biopharma's losses deepened to $5.49 per share in 2025 Q4 from a loss of $0.88 per share in 2024 Q4 (525.3% wider loss). Meanwhile, the company successfully narrowed its net loss to $-46.76 million in 2025 Q4, reducing losses by 35.4% compared to the $-72.44 million net loss reported in 2024 Q4. The Company has sustained losses for 8 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. Despite a wider per-share loss, the company reduced its overall net loss year-over-year, indicating improved cost management.

Price Action

The stock price of Sutro Biopharma has climbed 3.09% during the latest trading day, has tumbled 9.20% during the most recent full trading week, and has jumped 9.05% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Sutro Biopharma (STRO) shares after a revenue drop quarter-over-quarter on the financial report release date and holding for 30 days delivered moderate returns but came with high volatility and risk. The strategy's CAGR was 9.43%, trailing the benchmark by 1.33 percentage points. With a maximum drawdown of 91.93% and a Sharpe ratio of 0.08, the strategy indicated a challenging risk-return profile, highlighting the importance of risk management in such a volatile scenario.

CEO Commentary

Jane Chung, CEO of Sutro Biopharma, emphasized 2026 as a pivotal year driven by disciplined clinical execution and initial data from its ADC platform. She highlighted progress in three cohorts of the Phase 1 trial for STRO-004, a potential best-in-class Tissue Factor ADC, with initial data expected mid-2026. The CEO noted acceleration of STRO-227 (PTK7 dual-payload ADC) toward 2026 IND submission and the clinic entry of the Astellas-partnered iADC program. She underscored the extended cash runway into Q2 2028, supported by $110 million in recent financing, and expressed confidence in leveraging Sutro’s platform to deliver differentiated ADCs with best-in-class potential. The tone was optimistic, reflecting strategic focus on innovation and financial stewardship.

Guidance

Sutro provided forward-looking guidance including: (1) initial clinical data from STRO-004 in mid-2026, (2) IND submission for STRO-227 in 2026, (3) continued patient dosing in the Astellas TROP2 iADC program, and (4) cash runway extended to at least Q2 2028, excluding additional milestones. The company expects collaboration revenue from Astellas and Ipsen, with milestone payments tied to IND progress and clinical triggers. Financially, 2025 revenue was $102.48 million (vs. prior-year $62.04 million), with operating expenses declining to $207.4 million (2024: $300.5 million). Cash, equivalents, and securities totaled $141.4 million as of December 31, 2025.

Additional News

Sutro Biopharma recently completed a $110 million underwritten stock offering, significantly strengthening its cash position and extending its runway to Q2 2028. The company also announced accelerated development timelines for its ADC pipeline, including STRO-227 and the Astellas-partnered iADC program. Additionally, Sutro highlighted collaboration milestones with Astellas and Ipsen, with revenue and payments tied to clinical and regulatory progress. These moves underscore the company’s strategic focus on advancing its ADC platform and securing long-term financial stability.